Olema Pharmaceuticals
OLMA
126 hedge funds and large institutions have $668M invested in Olema Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 41 increasing their positions, 36 reducing their positions, and 16 closing their positions.
4,437% more call options, than puts
Call options by funds: $5.76M | Put options by funds: $127K
122% more capital invested
Capital invested by funds: $301M → $668M (+$368M)
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
14% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 36
3% more funds holding
Funds holding: 122 → 126 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.59% less ownership
Funds ownership: 103.08% → 99.49% (-3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$5.61M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$5.13M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.16M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$3.72M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$3.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$10.1M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$7.73M |
| 3 |
Millennium Management
New York
|
-$5.64M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.83M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$2.63M |
OLMA Hedge Fund Activity: Q3 2025 in Review
126 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q3 2025, worth a combined $668M — up 122% from $301M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new OLMA positions and 16 closed out — a net gain of 5 holders — while 41 added to existing stakes and 36 trimmed.
The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $5.61M. The largest seller was MPM BioImpact, exiting entirely with an estimated $10.1M sold.
- 126 institutional investors held Olema Pharmaceuticals (OLMA) as of Q3 2025, up from 122 in Q2 2025.
- Funds reported $668M of Olema Pharmaceuticals stock for Q3 2025, up 122% quarter-over-quarter.
- 21 funds opened new Olema Pharmaceuticals positions in Q3 2025 and 16 closed out, a net change of +5 holders.
- The largest Olema Pharmaceuticals buyer in Q3 2025 was Silverarc Capital Management, an estimated $5.61M added.
- The largest Olema Pharmaceuticals seller in Q3 2025 was MPM BioImpact, an estimated $10.1M sold.
Based on aggregated 13F filings for Q3 2025.